-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Guide: National price limit and volume forecast!national product price limit estimatethis national price forecast, mainly based on two points
1, the evaluation of the product counterpart enterprise, the rule of the historical bid price2, the same common name, the same specifications of all manufacturers bid price referencetable 1: the third batch of national product stakes corresponding specifications may limit price (not considering the difference price)(information source:special note: retail does not count, some channels do not countTable 2: the third batch of national products corresponding specifications may purchase(source of information: Fengyun medicine talk finishing)feng yun brief review:1, lie win: in the process of sorting the data found that some products are lying in, really strength and luck, congratulations, congratulations!2, part of the lack of rules: although the country in the amount of the report is 86 rules, but the final announcement of the time may be less than 86, in 80 or so of the standard, even less than 80, wait and see!3, more than 10 billion: according to the current forecast price and the volume, the overall amount reached nearly 18 billion yuan;according to the collection of health insurance fund balance retention incentive policy, then the entire health care system can get more than 4 billion yuan of incentive "funds." The non-winning has a greater impact4, for reference only: data for past data reference, such as Moxisha xing injection statistics will not count the number of small needles? Most of the sales of some products are in retail and channels, this part of the data is difficult to statistically accurate; 5, just started: there is a phenomenon, is that some products belong to the super-rise period, at this time the health insurance fund balance how to calculate? These products must be used in excess, such as the left ethyl lasitan two dosage forms, for Grillo, Vigretin, apixaban, linamine don't know how the health care bureau is thinking about this?